Estudos de medicamentos biosimilares
Carregando...
Data
2010-09-01
Autores
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Tipo
Artigo
Direito de acesso
Acesso aberto
Resumo
In Brazil, the registration of new drugs is carried out only when the regulatory agency (Anvisa, acronym in Portuguese) is fully satisfied with the evidence of their quality, efficacy and safety, presented by a pharmaceutical industry that strive for this registration. With the patent expiration, pharmaceutical companies are attracted to produce biological medicines called biosimilar or biogenerics or simply generics, whose approval may result in reduced treatment costs. But it is necessary that the biosimilar be, at least, equally efective and safe and without contaminants in relation to the original. Recent consensus guidelines aim to establish criteria for efcacy and safety of these medicines. Preclinical studies in vitro and in vivo, the origin of raw materials and clinical studies phase I, II and III are recommended for biosimilar medicine registration in the international market. Low molecular weight heparins are found in this situation. In this review we specifcally addressed this type of medicine, which could serve as a benchmark for other biosimilar medicines.
Descrição
Palavras-chave
Drugs, Generic, Heparin, Low-molecular-weight, Practice guidelines as topic, Therapeutic equivalence, biosimilar drug, generic drug, low molecular weight heparin, unclassified drug, bioequivalence, clinical study, drug approval, drug efficacy, drug research, drug safety, practice guideline, registration
Idioma
Português
Como citar
Jornal Vascular Brasileiro, v. 9, n. 3, p. 141-144, 2010.
